Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod
Background: Humoral responses after SARS-CoV-2 vaccination are greatly impaired in multiple sclerosis (MS) patients on fingolimod. Effects of repeated vaccination and infections on long-term responses are unclear. Methods: Prospective study in 60 MS patients on fingolimod measuring humoral responses...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis 2024-03, Vol.30 (3), p.443-447 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 447 |
|---|---|
| container_issue | 3 |
| container_start_page | 443 |
| container_title | Multiple sclerosis |
| container_volume | 30 |
| creator | van Kempen, Zoé LE van Dam, Koos PJ Keijser, Jim BD Stalman, Eileen W Kummer, Laura YL Strijbis, Eva MM Steenhuis, Maurice ten Brinke, Anja van Ham, S. Marieke Kuijpers, Taco Rispens, Theo Eftimov, Filip Wieske, Luuk Killestein, Joep |
| description | Background:
Humoral responses after SARS-CoV-2 vaccination are greatly impaired in multiple sclerosis (MS) patients on fingolimod. Effects of repeated vaccination and infections on long-term responses are unclear.
Methods:
Prospective study in 60 MS patients on fingolimod measuring humoral responses after up to four vaccinations and 8 months after fourth vaccination.
Results:
Anti-WH1 antibody titers increased with each additional vaccination. At long-term follow-up titers increased further and most patients developed new humoral responses against the BA.1 omicron variant.
Conclusion:
Repeated SARS-CoV-2 vaccinations boost humoral immunity and, probably together with SARS-CoV-2 infections, induce humoral responses on the long-term in almost all patients. |
| doi_str_mv | 10.1177/13524585231207761 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10935618</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_13524585231207761</sage_id><sourcerecordid>2888034531</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-70d1c90a560f3ac10ee7bd6d927bd2839eeb18482ca69bfe5f2f6ae9b635b42c3</originalsourceid><addsrcrecordid>eNp1kUtv1DAQxy0EoqXwAbggS1y4pPUjjuMTqlblIW2F1AWukeOMt64Se7GTCr49s9pSXuppxjO_-XsehLzk7JRzrc-4VKJWrRKSC6Z1wx-RY15rXTGj2WP0MV_tgSPyrJQbxhCS6ik5ktrUouXimHxfp7gN8zKEaEcaostgC9Dk6fUypYyxDGWXYoFCrZ8hU5-WTDfnV5tqlb5Wgt5a57B4DghRGwcU8eD2T_To5YbuMAdxLhQjPsRtGsOUhufkibdjgRd39oR8eXfxefWhWn96_3F1vq5czc1caTZwZ5hVDfPSOs4AdD80gxFoRCsNQM_buhXONqb3oLzwjQXTN1L1tXDyhLw96O6WfoLBYSc4VbfLYbL5R5ds6P7OxHDdbdNtx5mRquEtKry5U8jp2wJl7qZQHIyjjZCW0om2bZmsleSIvv4HvcFt4WaRMjiC3l8JKX6gXE6lZPD33XDW7Q_b_XdYrHn15xj3Fb8uicDpASh2C7-_fVjxJ67FrPc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2956070776</pqid></control><display><type>article</type><title>Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod</title><source>SAGE Complete A-Z List</source><source>MEDLINE</source><creator>van Kempen, Zoé LE ; van Dam, Koos PJ ; Keijser, Jim BD ; Stalman, Eileen W ; Kummer, Laura YL ; Strijbis, Eva MM ; Steenhuis, Maurice ; ten Brinke, Anja ; van Ham, S. Marieke ; Kuijpers, Taco ; Rispens, Theo ; Eftimov, Filip ; Wieske, Luuk ; Killestein, Joep</creator><creatorcontrib>van Kempen, Zoé LE ; van Dam, Koos PJ ; Keijser, Jim BD ; Stalman, Eileen W ; Kummer, Laura YL ; Strijbis, Eva MM ; Steenhuis, Maurice ; ten Brinke, Anja ; van Ham, S. Marieke ; Kuijpers, Taco ; Rispens, Theo ; Eftimov, Filip ; Wieske, Luuk ; Killestein, Joep</creatorcontrib><description>Background:
Humoral responses after SARS-CoV-2 vaccination are greatly impaired in multiple sclerosis (MS) patients on fingolimod. Effects of repeated vaccination and infections on long-term responses are unclear.
Methods:
Prospective study in 60 MS patients on fingolimod measuring humoral responses after up to four vaccinations and 8 months after fourth vaccination.
Results:
Anti-WH1 antibody titers increased with each additional vaccination. At long-term follow-up titers increased further and most patients developed new humoral responses against the BA.1 omicron variant.
Conclusion:
Repeated SARS-CoV-2 vaccinations boost humoral immunity and, probably together with SARS-CoV-2 infections, induce humoral responses on the long-term in almost all patients.</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/13524585231207761</identifier><identifier>PMID: 37942812</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Antibodies, Viral ; COVID-19 ; COVID-19 Vaccines ; Fingolimod Hydrochloride ; Humans ; Humoral immunity ; Multiple Sclerosis ; Prospective Studies ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Short Reports ; Vaccination</subject><ispartof>Multiple sclerosis, 2024-03, Vol.30 (3), p.443-447</ispartof><rights>The Author(s), 2023</rights><rights>The Author(s), 2023 2023 SAGE Publications</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c419t-70d1c90a560f3ac10ee7bd6d927bd2839eeb18482ca69bfe5f2f6ae9b635b42c3</cites><orcidid>0000-0001-6705-5864 ; 0000-0001-9557-5381 ; 0000-0001-9600-1312 ; 0009-0007-4474-545X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/13524585231207761$$EPDF$$P50$$Gsage$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/13524585231207761$$EHTML$$P50$$Gsage$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37942812$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Kempen, Zoé LE</creatorcontrib><creatorcontrib>van Dam, Koos PJ</creatorcontrib><creatorcontrib>Keijser, Jim BD</creatorcontrib><creatorcontrib>Stalman, Eileen W</creatorcontrib><creatorcontrib>Kummer, Laura YL</creatorcontrib><creatorcontrib>Strijbis, Eva MM</creatorcontrib><creatorcontrib>Steenhuis, Maurice</creatorcontrib><creatorcontrib>ten Brinke, Anja</creatorcontrib><creatorcontrib>van Ham, S. Marieke</creatorcontrib><creatorcontrib>Kuijpers, Taco</creatorcontrib><creatorcontrib>Rispens, Theo</creatorcontrib><creatorcontrib>Eftimov, Filip</creatorcontrib><creatorcontrib>Wieske, Luuk</creatorcontrib><creatorcontrib>Killestein, Joep</creatorcontrib><title>Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>Background:
Humoral responses after SARS-CoV-2 vaccination are greatly impaired in multiple sclerosis (MS) patients on fingolimod. Effects of repeated vaccination and infections on long-term responses are unclear.
Methods:
Prospective study in 60 MS patients on fingolimod measuring humoral responses after up to four vaccinations and 8 months after fourth vaccination.
Results:
Anti-WH1 antibody titers increased with each additional vaccination. At long-term follow-up titers increased further and most patients developed new humoral responses against the BA.1 omicron variant.
Conclusion:
Repeated SARS-CoV-2 vaccinations boost humoral immunity and, probably together with SARS-CoV-2 infections, induce humoral responses on the long-term in almost all patients.</description><subject>Antibodies, Viral</subject><subject>COVID-19</subject><subject>COVID-19 Vaccines</subject><subject>Fingolimod Hydrochloride</subject><subject>Humans</subject><subject>Humoral immunity</subject><subject>Multiple Sclerosis</subject><subject>Prospective Studies</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Short Reports</subject><subject>Vaccination</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>EIF</sourceid><recordid>eNp1kUtv1DAQxy0EoqXwAbggS1y4pPUjjuMTqlblIW2F1AWukeOMt64Se7GTCr49s9pSXuppxjO_-XsehLzk7JRzrc-4VKJWrRKSC6Z1wx-RY15rXTGj2WP0MV_tgSPyrJQbxhCS6ik5ktrUouXimHxfp7gN8zKEaEcaostgC9Dk6fUypYyxDGWXYoFCrZ8hU5-WTDfnV5tqlb5Wgt5a57B4DghRGwcU8eD2T_To5YbuMAdxLhQjPsRtGsOUhufkibdjgRd39oR8eXfxefWhWn96_3F1vq5czc1caTZwZ5hVDfPSOs4AdD80gxFoRCsNQM_buhXONqb3oLzwjQXTN1L1tXDyhLw96O6WfoLBYSc4VbfLYbL5R5ds6P7OxHDdbdNtx5mRquEtKry5U8jp2wJl7qZQHIyjjZCW0om2bZmsleSIvv4HvcFt4WaRMjiC3l8JKX6gXE6lZPD33XDW7Q_b_XdYrHn15xj3Fb8uicDpASh2C7-_fVjxJ67FrPc</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>van Kempen, Zoé LE</creator><creator>van Dam, Koos PJ</creator><creator>Keijser, Jim BD</creator><creator>Stalman, Eileen W</creator><creator>Kummer, Laura YL</creator><creator>Strijbis, Eva MM</creator><creator>Steenhuis, Maurice</creator><creator>ten Brinke, Anja</creator><creator>van Ham, S. Marieke</creator><creator>Kuijpers, Taco</creator><creator>Rispens, Theo</creator><creator>Eftimov, Filip</creator><creator>Wieske, Luuk</creator><creator>Killestein, Joep</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>AFRWT</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6705-5864</orcidid><orcidid>https://orcid.org/0000-0001-9557-5381</orcidid><orcidid>https://orcid.org/0000-0001-9600-1312</orcidid><orcidid>https://orcid.org/0009-0007-4474-545X</orcidid></search><sort><creationdate>20240301</creationdate><title>Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod</title><author>van Kempen, Zoé LE ; van Dam, Koos PJ ; Keijser, Jim BD ; Stalman, Eileen W ; Kummer, Laura YL ; Strijbis, Eva MM ; Steenhuis, Maurice ; ten Brinke, Anja ; van Ham, S. Marieke ; Kuijpers, Taco ; Rispens, Theo ; Eftimov, Filip ; Wieske, Luuk ; Killestein, Joep</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-70d1c90a560f3ac10ee7bd6d927bd2839eeb18482ca69bfe5f2f6ae9b635b42c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antibodies, Viral</topic><topic>COVID-19</topic><topic>COVID-19 Vaccines</topic><topic>Fingolimod Hydrochloride</topic><topic>Humans</topic><topic>Humoral immunity</topic><topic>Multiple Sclerosis</topic><topic>Prospective Studies</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Short Reports</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Kempen, Zoé LE</creatorcontrib><creatorcontrib>van Dam, Koos PJ</creatorcontrib><creatorcontrib>Keijser, Jim BD</creatorcontrib><creatorcontrib>Stalman, Eileen W</creatorcontrib><creatorcontrib>Kummer, Laura YL</creatorcontrib><creatorcontrib>Strijbis, Eva MM</creatorcontrib><creatorcontrib>Steenhuis, Maurice</creatorcontrib><creatorcontrib>ten Brinke, Anja</creatorcontrib><creatorcontrib>van Ham, S. Marieke</creatorcontrib><creatorcontrib>Kuijpers, Taco</creatorcontrib><creatorcontrib>Rispens, Theo</creatorcontrib><creatorcontrib>Eftimov, Filip</creatorcontrib><creatorcontrib>Wieske, Luuk</creatorcontrib><creatorcontrib>Killestein, Joep</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Kempen, Zoé LE</au><au>van Dam, Koos PJ</au><au>Keijser, Jim BD</au><au>Stalman, Eileen W</au><au>Kummer, Laura YL</au><au>Strijbis, Eva MM</au><au>Steenhuis, Maurice</au><au>ten Brinke, Anja</au><au>van Ham, S. Marieke</au><au>Kuijpers, Taco</au><au>Rispens, Theo</au><au>Eftimov, Filip</au><au>Wieske, Luuk</au><au>Killestein, Joep</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2024-03-01</date><risdate>2024</risdate><volume>30</volume><issue>3</issue><spage>443</spage><epage>447</epage><pages>443-447</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><abstract>Background:
Humoral responses after SARS-CoV-2 vaccination are greatly impaired in multiple sclerosis (MS) patients on fingolimod. Effects of repeated vaccination and infections on long-term responses are unclear.
Methods:
Prospective study in 60 MS patients on fingolimod measuring humoral responses after up to four vaccinations and 8 months after fourth vaccination.
Results:
Anti-WH1 antibody titers increased with each additional vaccination. At long-term follow-up titers increased further and most patients developed new humoral responses against the BA.1 omicron variant.
Conclusion:
Repeated SARS-CoV-2 vaccinations boost humoral immunity and, probably together with SARS-CoV-2 infections, induce humoral responses on the long-term in almost all patients.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>37942812</pmid><doi>10.1177/13524585231207761</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-6705-5864</orcidid><orcidid>https://orcid.org/0000-0001-9557-5381</orcidid><orcidid>https://orcid.org/0000-0001-9600-1312</orcidid><orcidid>https://orcid.org/0009-0007-4474-545X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2024-03, Vol.30 (3), p.443-447 |
| issn | 1352-4585 1477-0970 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10935618 |
| source | SAGE Complete A-Z List; MEDLINE |
| subjects | Antibodies, Viral COVID-19 COVID-19 Vaccines Fingolimod Hydrochloride Humans Humoral immunity Multiple Sclerosis Prospective Studies SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Short Reports Vaccination |
| title | Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T07%3A02%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Longitudinal%20increase%20of%20humoral%20responses%20after%20four%20SARS-CoV-2%20vaccinations%20and%20infection%20in%20MS%20patients%20on%20fingolimod&rft.jtitle=Multiple%20sclerosis&rft.au=van%20Kempen,%20Zo%C3%A9%20LE&rft.date=2024-03-01&rft.volume=30&rft.issue=3&rft.spage=443&rft.epage=447&rft.pages=443-447&rft.issn=1352-4585&rft.eissn=1477-0970&rft_id=info:doi/10.1177/13524585231207761&rft_dat=%3Cproquest_pubme%3E2888034531%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2956070776&rft_id=info:pmid/37942812&rft_sage_id=10.1177_13524585231207761&rfr_iscdi=true |